Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19

Competing Interest Statement

AM, JB and MU filed a patent application on the use of CMCS on COVID-19 patients. The other authors declare no competing interests.

Clinical Trial

ClinicalTrials.gov NCT04573153

Funding Statement

This work was supported by Knut and Alice Wallenberg Foundation. The authors would like to thank ChromaDex (Irvine, CA, USA) for providing NR for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study has been approved by the ethics committee of Istanbul Medipol University. Decision No:45 Decision Date: 28/05/2020 Members of Ethics Committee: Professor Hanefi OZBEK Professor Gurkan OZTURK Professor Fulya IlCin GONENC Professor Abdulbari BENER Associate Professor Ali OZTURK Associate Professor Bahri TEKER Associate Professor Muhammed Fatih EVCIMIK

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes